scholarly article | Q13442814 |
P2093 | author name string | Lior H | |
Arbus GS | |||
Karmali MA | |||
Petric M | |||
Fleming PC | |||
Lim C | |||
P433 | issue | 5 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Escherichia coli | Q25419 |
P1104 | number of pages | 8 | |
P304 | page(s) | 775-782 | |
P577 | publication date | 1985-05-01 | |
P1433 | published in | Journal of Infectious Diseases | Q4051141 |
P1476 | title | The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli | |
P478 | volume | 151 |
Q37091677 | A Novel Shiga Toxin 1a-Converting Bacteriophage of Shigella sonnei With Close Relationship to Shiga Toxin 2-Converting Pages of Escherichia coli |
Q39799605 | A PCR-based assay for the detection of Escherichia coli Shiga-like toxin genes in ground beef |
Q42585716 | A case-control study of selected pathogens including verocytotoxigenic Escherichia coli in calf diarrhea on an Ontario veal farm |
Q33371578 | A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders |
Q33384189 | A dietary non-human sialic acid may facilitate hemolytic-uremic syndrome |
Q33447751 | A family outbreak of hemolytic-uremic syndrome associated with verotoxin-producing Escherichia coli serotype O157:H7. |
Q47108133 | A hemolytic-uremic syndrome-associated strain O113:H21 Shiga toxin-producing Escherichia coli specifically expresses a transcriptional module containing dicA and is related to gene network dysregulation in Caco-2 cells |
Q42124163 | A longitudinal study of Vero cytotoxin producing Escherichia coli in cattle calves in Sri Lanka |
Q39871476 | A multi-level approach for investigating socio-economic and agricultural risk factors associated with rates of reported cases of Escherichia coli O157 in humans in Alberta, Canada |
Q27622010 | A mutant Shiga-like toxin IIe bound to its receptor Gb(3): structure of a group II Shiga-like toxin with altered binding specificity |
Q38294429 | A mutational analysis of the globotriaosylceramide-binding sites of verotoxin VT1. |
Q44245678 | A novel caspase dependent pathway is involved in apoptosis of human endothelial cells by Shiga toxins |
Q35125841 | A novel mechanism of bacterial toxin transfer within host blood cell-derived microvesicles |
Q37016559 | A plasmid of enterohemorrhagic Escherichia coli O157:H7 is required for expression of a new fimbrial antigen and for adhesion to epithelial cells |
Q33494314 | A prospective study of exposure to verotoxin-producing Escherichia coli among Canadian children with haemolytic uraemic syndrome. The CPKDRC co-investigators |
Q33427445 | A rapid and sensitive method to measure the functional activity of Shiga toxins in human serum |
Q33997875 | A reverse-sandwich enzyme-linked immunosorbent assay for verocytotoxin 1 and 2 antibodies in human and bovine sera |
Q33410645 | A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2. |
Q42254722 | A stochastic model for transmission, extinction and outbreak of Escherichia coli O157:H7 in cattle as affected by ambient temperature and cleaning practices. |
Q34065066 | A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli O157:H7. |
Q33401658 | A time for reappraisal of "atypical" hemolytic uremic syndrome: should all patients be treated the same? |
Q33418645 | ADAMTS-13 in the Diagnosis and Management of Thrombotic Microangiopathies |
Q34922868 | Action of shiga toxin type-2 and subtilase cytotoxin on human microvascular endothelial cells |
Q31948409 | Activation of the caspase cascade during Stx1-induced apoptosis in Burkitt's lymphoma cells |
Q33488517 | Acute renal failure associated withCandida albicans infection |
Q33498942 | Acute renal failure due to hemolytic uremic syndrome in adult patients |
Q33385402 | Acute renal failure in a female adolescent with leukemia in remission |
Q35109009 | Acute renal tubular necrosis and death of mice orally infected with Escherichia coli strains that produce Shiga-like toxin type II |
Q40937562 | Adaptation of Escherichia coli O157:H7 to pH alters membrane lipid composition, verotoxin secretion, and resistance to simulated gastric fluid acid |
Q40146295 | Adherence of enterohemorrhagic Escherichia coli strains to a human colonic epithelial cell line (T84). |
Q33376471 | Adult hemolytic-uremic syndrome associated with urosepsis due to Shigatoxin-producing Escherichia coli O138:H-. |
Q36997934 | Affinity purification and characterization of Shiga-like toxin II and production of toxin-specific monoclonal antibodies |
Q36068651 | Affinity-Based Screening of Tetravalent Peptides Identifies Subtype-Selective Neutralizers of Shiga Toxin 2d, a Highly Virulent Subtype, by Targeting a Unique Amino Acid Involved in Its Receptor Recognition |
Q39341582 | Age-Related Changes of Serum Soluble Interleukin 9 Receptor (sIL-9Rα) in Healthy Subjects |
Q33380037 | Age-dependent decrease in serum soluble interferon-gamma receptor (sIFN-gammaR) in healthy Japanese individuals; population study of serum sIFN-gammaR level in Japanese |
Q73409149 | Alpha-galactose based neoglycopeptides. Inhibition of verotoxin binding to globotriosylceramide |
Q36785336 | Alteration of the carbohydrate binding specificity of verotoxins from Gal alpha 1-4Gal to GalNAc beta 1-3Gal alpha 1-4Gal and vice versa by site-directed mutagenesis of the binding subunit |
Q42941754 | Alteration of the glycolipid binding specificity of the pig edema toxin from globotetraosyl to globotriaosyl ceramide alters in vivo tissue targetting and results in a verotoxin 1-like disease in pigs |
Q33488951 | Altered renovascular resistance after spontaneous recovery from hemolytic uremic syndrome |
Q36957798 | An enzymatic mutant of Shiga-like toxin II variant is a vaccine candidate for edema disease of swine |
Q39894763 | An enzyme-linked immunosorbent assay-based isolation procedure for verotoxigenic Escherichia coli. |
Q54523532 | An epidemiological study on Verotoxin-producing Escherichia coli (VTEC) infection among population of northern region of Iran (Mazandaran and Golestan provinces). |
Q42947533 | An orally applicable Shiga toxin neutralizer functions in the intestine to inhibit the intracellular transport of the toxin. |
Q54442932 | An outbreak of Escherichia coli O157:H7 infection in southern Sweden associated with consumption of fermented sausage; aspects of sausage production that increase the risk of contamination. |
Q33504966 | An unusual case of microangiopathic haemolytic anaemia associated with enterohaemorrhagic Escherichia coli O113:H21 infection, a verocytotoxin-2/shiga toxin-2 producing serotype |
Q33719498 | Analysis of Escherichia coli O157:H7 survival in ovine or bovine manure and manure slurry. |
Q54355968 | Antibodies anti-Shiga toxin 2 B subunit from chicken egg yolk: isolation, purification and neutralization efficacy. |
Q33429198 | Antibodies to Escherichia coli O157 in patients with haemorrhagic colitis and haemolytic uraemic syndrome |
Q40186741 | Antibodies to shiga holotoxin and to two synthetic peptides of the B subunit in sera of patients with Shigella dysenteriae 1 dysentery |
Q33337454 | Antibody response to Shiga toxins Stx2 and Stx1 in children with enteropathic hemolytic-uremic syndrome |
Q33877305 | Antibody-based protection of gnotobiotic piglets infected with Escherichia coli O157:H7 against systemic complications associated with Shiga toxin 2. |
Q33445938 | Anticytotoxin-neutralizing antibodies in immune globulin preparations: potential use in hemolytic-uremic syndrome |
Q42126833 | Antidiarrheal Agents: More to the Apple Sauce Than You Might Think: Treating infectious diarrheas. |
Q44354606 | Antigenic heterogeneity of Escherichia coli verotoxins |
Q33501527 | Apoptosis of renal cortical cells in the hemolytic-uremic syndrome: in vivo and in vitro studies |
Q33496262 | Are there restrictions to vaccinating a child who has recovered from hemolytic uremic syndrome? |
Q33374555 | Association between severity of gastrointestinal prodrome and long-term prognosis in classic hemolytic-uremic syndrome |
Q37058874 | Association of genomic O island 122 of Escherichia coli EDL 933 with verocytotoxin-producing Escherichia coli seropathotypes that are linked to epidemic and/or serious disease |
Q40157780 | Attaching and effacing adherence of Vero cytotoxin-producing Escherichia coli to rabbit intestinal epithelium in vivo |
Q33494589 | Atypical (non-diarrhea-associated) hemolytic-uremic syndrome in childhood |
Q33337686 | BMT: Bone Marrow Transplant Associated Thrombotic Microangiopathy |
Q40160063 | Bacterial endotoxin both enhances and inhibits the toxicity of Shiga-like toxin II in rabbits and mice |
Q39627920 | Bacterial gastroenteritis. |
Q39567179 | Bacterial-induced diarrhoea |
Q38519709 | Binding of shiga toxin 2e to porcine erythrocytes in vivo and in vitro |
Q38718403 | Biofilm formation, invasiveness and colicinogeny in locus of enterocyte and effacement negative O113:H21 Shigatoxigenic Escherichia coli |
Q57528836 | Bioinspired Functionalized Nanoparticles as Tools for Detection, Quantification and Targeting of Biomolecules |
Q38936714 | Biological roles of glycans |
Q35026634 | Bovine non-O157 Shiga toxin 2-containing Escherichia coli isolates commonly possess stx2-EDL933 and/or stx2vhb subtypes |
Q43476342 | Bovine reservoir for verotoxin-producing Escherichia coli O157:H7. |
Q48192053 | Brainstem mechanisms of autonomic dysfunction in encephalopathy-associated Shiga toxin 2 intoxication |
Q41996638 | British Escherichia coli O157 in Cattle Study (BECS): to determine the prevalence of E. coli O157 in herds with cattle destined for the food chain. |
Q40847307 | CD40 ligand, Bcl-2, and Bcl-xL spare group I Burkitt lymphoma cells from CD77-directed killing via Verotoxin-1 B chain but fail to protect against the holotoxin |
Q36503520 | Cattle as a possible source of verocytotoxin-producing Escherichia coli O157 infections in man. |
Q54763061 | Cattle as reservoir of verotoxin-producing Escherichia coli O157:H7. |
Q33415947 | Causes of the haemolytic uraemic syndrome |
Q33396647 | Change in conformation with reduction of alpha-helix content causes loss of neutrophil binding activity in fully cytotoxic Shiga toxin 1. |
Q38341459 | Characteristics of binding of Escherichia coli serotype O157:H7 strain CL-49 to purified intestinal mucin |
Q42574372 | Characteristics of verotoxigenic Escherichia coli from pigs |
Q40332508 | Characterization and Virulence Potential of Serogroup O113 Shiga Toxin-Producing Escherichia coli Strains Isolated from Beef and Cattle in the United States. |
Q40724731 | Characterization and evidence of mobilization of the LEE pathogenicity island of rabbit-specific strains of enteropathogenic Escherichia coli |
Q37156215 | Characterization of Escherichia coli serotype O157:H7. |
Q33553290 | Characterization of Saa, a novel autoagglutinating adhesin produced by locus of enterocyte effacement-negative Shiga-toxigenic Escherichia coli strains that are virulent for humans |
Q36818691 | Characterization of Shiga Toxin Subtypes and Virulence Genes in Porcine Shiga Toxin-Producing Escherichia coli |
Q42859529 | Characterization of Shiga-like toxin I B subunit purified from overproducing clones of the SLT-I B cistron |
Q33884882 | Characterization of a shiga toxin-, intimin-, and enterotoxin hemolysin-producing Escherichia coli ONT:H25 strain commonly isolated from healthy cattle |
Q39823954 | Characterization of an RTX toxin from enterohemorrhagic Escherichia coli O157:H7. |
Q37151695 | Characterization of flagella purified from enterohemorrhagic, vero-cytotoxin-producing Escherichia coli serotype O157:H7. |
Q33328717 | Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1 |
Q41918220 | Chemokine expression in human astrocytes in response to shiga toxin 2 |
Q33372575 | Childhood hemolytic uremic syndrome is associated with adolescent-onset diabetes mellitus |
Q33370432 | Chromosomal dynamism in progeny of outbreak-related sorbitol-fermenting enterohemorrhagic Escherichia coli O157:NM. |
Q33412570 | Chronic sequelae of E. coli O157: systematic review and meta-analysis of the proportion of E. coli O157 cases that develop chronic sequelae |
Q33345355 | Circulating granulocyte colony-stimulating factor, C-X-C, and C-C chemokines in children with Escherichia coli O157:H7 associated hemolytic uremic syndrome |
Q33331088 | Circulating levels of transforming growth factor-beta1 and lymphokines among children with hemolytic uremic syndrome |
Q33491119 | Cisplatin-associated hemolytic uremic syndrome |
Q27306436 | Clade 8 and Clade 6 Strains of Escherichia coli O157:H7 from Cattle in Argentina have Hypervirulent-Like Phenotypes |
Q37336265 | Clinical evaluation of a real-time PCR assay for identification of Salmonella, Shigella, Campylobacter (Campylobacter jejuni and C. coli), and shiga toxin-producing Escherichia coli isolates in stool specimens. |
Q33385986 | Clinical practice. Today's understanding of the haemolytic uraemic syndrome |
Q54651961 | Clinical signs and lesions in gnotobiotic pigs inoculated with Shiga-like toxin I from Escherichia coli. |
Q33424960 | Clinical-Pathological Conference Series from the Medical University of Graz Case No 155: 26-year-old woman in third trimester of pregnancy with epigastric pain and thrombocytopenia |
Q39965419 | Cloning and expression of the genes specifying Shiga-like toxin production in Escherichia coli H19. |
Q68090249 | Cloning and sequencing of a Shiga-like toxin II-related gene from Escherichia coli O157:H7 strain 7279 |
Q36194407 | Cloning and sequencing of the genes for Shiga toxin from Shigella dysenteriae type 1. |
Q37007761 | Cloning of genes for production of Escherichia coli Shiga-like toxin type II |
Q37162735 | Close association of verotoxin (Shiga-like toxin) production with enterohemolysin production in strains of Escherichia coli |
Q35042338 | Commensal E. coli Stx2 lysogens produce high levels of phages after spontaneous prophage induction |
Q36060108 | Comparative Characterization of Shiga Toxin Type 2 and Subtilase Cytotoxin Effects on Human Renal Epithelial and Endothelial Cells Grown in Monolayer and Bilayer Conditions |
Q58588700 | Comparative Genomics and Characterization of the Late Promoter R' from Shiga Toxin Prophages in |
Q59391030 | Comparative Genomics and Characterization of the Late Promoter pR’ from Shiga Toxin Prophages in Escherichia coli |
Q77390584 | Comparison of 14 PCR systems for the detection and subtyping of stx genes in Shiga-toxin-producing Escherichia coli |
Q33947074 | Comparison of Shiga toxin-producing Escherichia coli detection methods using clinical stool samples |
Q40133558 | Comparison of a Shiga Toxin Enzyme-Linked Immunosorbent Assay and Two Types of PCR for Detection of Shiga Toxin-Producing Escherichia coli in Human Stool Specimens |
Q37116299 | Comparison of a direct fecal Shiga-like toxin assay and sorbitol-MacConkey agar culture for laboratory diagnosis of enterohemorrhagic Escherichia coli infection |
Q41896763 | Comparison of clinical and epidemiological features of Shiga toxin-producing Escherichia coli O157 and non-O157 infections in British Columbia, 2009 to 2011. |
Q54567409 | Comparison of ribosome-inactivating proteins in the induction of apoptosis. |
Q36977977 | Comparison of the glycolipid receptor specificities of Shiga-like toxin type II and Shiga-like toxin type II variants |
Q33498518 | Comparison of the western blot assay with the neutralizing-antibody and enzyme-linked immunosorbent assays for measuring antibody to verocytotoxin 1. |
Q33404523 | Comparison of three different methods for detection of Shiga toxin-producing Escherichia coli in a tertiary pediatric care center |
Q35132357 | Comparisons of native Shiga toxins (Stxs) type 1 and 2 with chimeric toxins indicate that the source of the binding subunit dictates degree of toxicity |
Q33654317 | Complete Genome Sequences of Two Escherichia coli O145:H28 Outbreak Strains of Food Origin. |
Q33406356 | Comprehensive analysis of glomerular mRNA expression of pro- and antithrombotic genes in atypical haemolytic-uremic syndrome (aHUS). |
Q33494319 | Concentrations of interleukin 6 and tumour necrosis factor in serum and stools of children with Shigella dysenteriae 1 infection. |
Q43254870 | Conditioned medium from enterohemorrhagic Escherichia coli-infected T84 cells inhibits signal transducer and activator of transcription 1 activation by gamma interferon |
Q92627201 | Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome |
Q36633507 | Contemporary issues: diseases with a food vector |
Q35220329 | Contribution of FliC to epithelial cell invasion by enterohemorrhagic Escherichia coli O113:H21. |
Q34358725 | Correlation between in vivo biofilm formation and virulence gene expression in Escherichia coli O104:H4. |
Q35102179 | Correlation of enterohemorrhagic Escherichia coli O157 prevalence in feces, hides, and carcasses of beef cattle during processing |
Q35075768 | Cross-reactive protection against enterohemorrhagic Escherichia coli infection by enteropathogenic E. coli in a mouse model |
Q33396586 | Culture confirmation of Escherichia coli serotype O157:H7 by direct immunofluorescence |
Q42978314 | Culture negative cytotoxin positive stools in community acquired diarrhoea |
Q33346852 | Current concepts in the diagnosis and management of thrombotic thrombocytopenic purpura |
Q27003211 | Current treatment of atypical hemolytic uremic syndrome |
Q33375457 | Current views on aetiology and management of haemolytic uraemic syndrome |
Q40282722 | Cytocompatibility and antibacterial activity of a PHBV membrane with surface-immobilized water-soluble chitosan and chondroitin-6-sulfate |
Q33399069 | Cytokine production is altered in monocytes from children with hemolytic uremic syndrome |
Q37020358 | Cytotoxicity of Shiga toxin for primary cultures of human colonic and ileal epithelial cells |
Q37151311 | DNA probes for Shiga-like toxins I and II and for toxin-converting bacteriophages |
Q40195165 | DNA probes to identify Shiga-like toxin I- and II-producing enteric bacterial pathogens isolated from patients with diarrhea in Thailand |
Q33329124 | Depletion of liver and splenic macrophages reduces the lethality of Shiga toxin-2 in a mouse model |
Q40174976 | Detection and characterization of the eae gene of Shiga-like toxin-producing Escherichia coli using polymerase chain reaction |
Q38847624 | Detection and prevalence of verotoxin-producing Escherichia coli O157 and non-O157 serotypes in a Canadian watershed |
Q33336219 | Detection of apoptosis in kidney biopsies of patients with D+ hemolytic uremic syndrome. |
Q33494833 | Detection of verocytotoxin from stool and serological testing of patients with diarrhea caused by Escherichia coli O157 : H7. |
Q33410450 | Detection of verotoxin in stool specimens |
Q47880128 | Detection of verotoxin-producing Escherichia coli O157:H7 by multiplex polymerase chain reaction |
Q37168692 | Determination by DNA hybridization of Shiga-like-toxin-producing Escherichia coli in children with diarrhea in Thailand |
Q39773693 | Determination of soluble tumor necrosis factor-α receptor type I (TNFRI) and II (TNFRII) in the urine of healthy Japanese subjects |
Q99636418 | Determining the long-term health burden and risk of sequelae for 14 foodborne infections in British Columbia, Canada: protocol for a retrospective population-based cohort study |
Q92783425 | Development and Validation of Shiga Toxin-Producing Escherichia coli Immunodiagnostic Assay |
Q40199718 | Development and evaluation of enzyme-linked immunosorbent assays for detection of shiga-like toxin I and shiga-like toxin II. |
Q28534818 | Dexamethasone rescues neurovascular unit integrity from cell damage caused by systemic administration of shiga toxin 2 and lipopolysaccharide in mice motor cortex |
Q24533466 | Diarrheagenic Escherichia coli |
Q39051292 | Diarrhoea caused byEscherichia coli |
Q42273167 | Differences in Shiga toxin and phage production among stx(2g)-positive STEC strains |
Q54658182 | Differences in verotoxin neutralizing activity of therapeutic immunoglobulins and sera from healthy controls. |
Q33367484 | Differential expression of function-related antigens on blood monocytes in children with hemolytic uremic syndrome |
Q40312938 | Differential virulence of clinical and bovine-biased enterohemorrhagic Escherichia coli O157:H7 genotypes in piglet and Dutch belted rabbit models |
Q33415795 | Direct acute tubular damage contributes to Shigatoxin-mediated kidney failure |
Q36999010 | Direct cytotoxic action of Shiga toxin on human vascular endothelial cells |
Q50135970 | Direct detection by PCR of Escherichia coli O157 and enteropathogens in patients with bloody diarrhea |
Q33963092 | Direct detection of Shiga toxigenic Escherichia coli strains belonging to serogroups O111, O157, and O113 by multiplex PCR. |
Q36519199 | Direct detection of verotoxin-producing Escherichia coli in stool samples by PCR. |
Q34534278 | Direct evidence of neuron impairment by oral infection with verotoxin-producing Escherichia coli O157:H- in mitomycin-treated mice. |
Q54296415 | Discovery of inhibitors of Shiga toxin type 2 by on-plate generation and screening of a focused compound library. |
Q33406110 | Disseminated prostatic carcinoma presenting with acute interstitial nephritis and microangiopathic haemolytic anaemia |
Q40374985 | Distinct binding properties of eaeA-negative verocytotoxin-producing Escherichia coli of serotype O113:H21. |
Q33388849 | Distinct physiologic and inflammatory responses elicited in baboons after challenge with Shiga toxin type 1 or 2 from enterohemorrhagic Escherichia coli |
Q41997764 | Distribution of Gb(3) Immunoreactivity in the Mouse Central Nervous System |
Q39570787 | Divergent signal transduction responses to infection with attaching and effacing Escherichia coli. |
Q35573487 | Diversity of Shiga Toxin-Producing Escherichia coli (STEC) O26:H11 Strains Examined via stx Subtypes and Insertion Sites of Stx and EspK Bacteriophages. |
Q45949070 | Draft Genome Sequences of Escherichia coli O113:H21 Strains Recovered from a Major Produce Production Region in California. |
Q91747714 | Dynamic Gene Network Analysis of Caco-2 Cell Response to Shiga Toxin-Producing Escherichia coli-Associated Hemolytic-Uremic Syndrome |
Q40426879 | Edema disease-like brain lesions in gnotobiotic piglets infected with Escherichia coli serotype O157:H7 |
Q42486029 | Effect of Shiga toxin 2 on water and ion transport in human colon in vitro |
Q33337469 | Effect of Shiga toxin and Shiga-like toxins on eukaryotic cells |
Q33849613 | Effect of shiga toxin and its subunits on cytokine induction in different cell lines |
Q33364452 | Effect of subinhibitory concentrations of antibiotics on extracellular Shiga-like toxin I. |
Q53946808 | Effect of subtherapeutic concentrations of tylosin on the inhibitory stringency of a mixed anaerobe continuous-flow culture of chicken microflora against Escherichia coli O157:H7. |
Q41771592 | Effect of the Food Additives Sodium Citrate and Disodium Phosphate on Shiga Toxin-Producing Escherichia coli and Production of stx-Phages and Shiga toxin |
Q33330389 | Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak |
Q41763522 | Effects of Escherichia coli subtilase cytotoxin and Shiga toxin 2 on primary cultures of human renal tubular epithelial cells |
Q26777059 | Effects of Mycotoxins on mucosal microbial infection and related pathogenesis |
Q34004015 | Effects of Shiga toxin 2 on lethality, fetuses, delivery, and puerperal behavior in pregnant mice |
Q34889826 | Effects of Shiga toxin type 2 on a bioengineered three-dimensional model of human renal tissue |
Q33498793 | Effects of TNF alpha on verocytotoxin cytotoxicity in purified human glomerular microvascular endothelial cells. |
Q34142282 | Effects of azithromycin on shiga toxin production by Escherichia coli and subsequent host inflammatory response |
Q37215545 | Effects of cycloheximide and puromycin on cytotoxic activity of Escherichia coli verocytotoxin (Shiga-like toxin). |
Q54302067 | Efficacy of recombinant human soluble thrombomodulin for childhood hemolytic uremic syndrome. |
Q39482675 | Electrophoretic mobilities of Escherichia coli O157:H7 and wild-type Escherichia coli strains. |
Q33360774 | Elevated levels of vascular endothelial growth factor in serum of patients with D+ HUS. |
Q39093646 | Emerging Public Health Challenges of Shiga Toxin-Producing Escherichia coli Related to Changes in the Pathogen, the Population, and the Environment |
Q41575546 | Endocytosis from coated pits of Shiga toxin: a glycolipid-binding protein from Shigella dysenteriae 1. |
Q33346344 | Endogenous glucocorticoids attenuate Shiga toxin-2-induced toxicity in a mouse model of haemolytic uraemic syndrome |
Q43110447 | Endothelial Dysfunction: The Secret Agent Driving Kidney Disease |
Q33389052 | Endothelial damage induced by Shiga toxins delivered by neutrophils during transmigration |
Q33752654 | Enhancement of susceptibility to Shiga toxin-producing Escherichia coli O157:H7 by protein calorie malnutrition in mice |
Q43086295 | Enterohaemorrhagic Escherichia coli O157:H7 target Peyer's patches in humans and cause attaching/effacing lesions in both human and bovine intestine |
Q33379683 | Enterohaemorrhagic Escherichia coli and Shigella dysenteriae type 1-induced haemolytic uraemic syndrome |
Q43422802 | Enterohaemorrhagic Escherichia coli serotype O157:H7 as an enteric pathogen in Irish children |
Q33497368 | Enterohemolytic phenotypes and genotypes of shiga toxin-producing Escherichia coli O111 strains from patients with diarrhea and hemolytic-uremic syndrome |
Q33402961 | Enterohemorrhagic E. coli (EHEC) pathogenesis |
Q33359877 | Enterohemorrhagic Escherichia coli associated with hemolytic-uremic syndrome in Chilean children |
Q38926009 | Enterohemorrhagic Escherichia coli colonization of human colonic epithelium in vitro and ex vivo |
Q39515881 | Enterohemorrhagic Escherichia coli induces apoptosis which augments bacterial binding and phosphatidylethanolamine exposure on the plasma membrane outer leaflet. |
Q50172861 | EnterohemorrhagicEscherichia coli O157:H7 possesses somatic (O) antigen identical with that ofSalmonella O301 |
Q33492004 | Enzyme-linked immunosorbent assay for detection of immunoglobulin G antibodies to Escherichia coli Vero cytotoxin 1 |
Q33501155 | Epidemic hemolytic-uremic syndrome in children |
Q33329451 | Epidemiology and diagnosis of Shiga toxin-producing Escherichia coli infections. |
Q33495990 | Epidemiology of infection due to Escherichia coli O157: a 3-year prospective study |
Q73207396 | Epigallocatechin gallate and gallocatechin gallate in green tea catechins inhibit extracellular release of Vero toxin from enterohemorrhagic Escherichia coli O157:H7 |
Q33377324 | Escherichia Coli O157: H7, a Cause of Hemorrhagic Colitis and Hemolytic Uremic Syndrome |
Q33343335 | Escherichia coli 'O' group serological responses and clinical correlations in epidemic HUS patients |
Q37287149 | Escherichia coli O157:H7 Strain EDL933 Harbors Multiple Functional Prophage-Associated Genes Necessary for the Utilization of 5-N-Acetyl-9-O-Acetyl Neuraminic Acid as a Growth Substrate |
Q33330315 | Escherichia coli O157:H7 and O157:H(-) strains that do not produce Shiga toxin: phenotypic and genetic characterization of isolates associated with diarrhea and hemolytic-uremic syndrome. |
Q68929313 | Escherichia coli O157:H7 infections associated with perforated appendicitis and chronic diarrhoea |
Q33498630 | Escherichia coli O157:H7--two case reports |
Q33394010 | Escherichia coli Shiga Toxin Mechanisms of Action in Renal Disease |
Q24604606 | Escherichia coli Subtilase Cytotoxin |
Q36250303 | Escherichia coli diarrhoea |
Q41476186 | Escherichia coli from Crohn's disease patient displays virulence features of enteroinvasive (EIEC), enterohemorragic (EHEC), and enteroaggregative (EAEC) pathotypes |
Q68927490 | Escherichia coli gastroenteritis: making sense of the new acronyms. Infectious Diseases and Immunization Committee, Canadian Paediatric Society |
Q40349623 | Escherichia coli verotoxin 1 mediates apoptosis in human HCT116 colon cancer cells by inducing overexpression of the GADD family of genes and S phase arrest |
Q54598931 | Escherichia coli verotoxin binding to human paediatric glomerular mesangial cells. |
Q33488736 | Escherichia coliO157:H7 and the Hemolytic–Uremic Syndrome |
Q37676422 | Etiology and mechanisms of acute infectious diarrhea in infants in the United States |
Q37229195 | Etiology of childhood diarrhea in Beijing, China |
Q40199630 | Etiology of childhood diarrhea in Korea |
Q39446323 | Evaluation of a microplate latex agglutination method (Verotox-F assay) for detecting and characterizing verotoxins (Shiga toxins) in Escherichia coli |
Q40006733 | Evaluation of an immunoassay for direct detection of Escherichia coli O157 in stool specimens |
Q36533106 | Evaluation of commercial latex reagents for identification of O157 and H7 antigens of Escherichia coli |
Q39629490 | Evaluation of commercial latex slide test for identifying Escherichia coli O157. |
Q40199619 | Evaluation of oligonucleotide probes for identification of shiga-like-toxin-producing Escherichia coli |
Q54405120 | Evaluation of three commercially available enzyme-linked immunosorbent assay kits for detection of Shiga toxin. |
Q36575178 | Evidence for a hybrid genomic island in verocytotoxin-producing Escherichia coli CL3 (serotype O113:H21) containing segments of EDL933 (serotype O157:H7) O islands 122 and 48. |
Q24651553 | Evidence that glutamic acid 167 is an active-site residue of Shiga-like toxin I |
Q24633154 | Evidence that verotoxins (Shiga-like toxins) from Escherichia coli bind to P blood group antigens of human erythrocytes in vitro |
Q64886207 | Exosome-associated Shiga toxin 2 is released from cells and causes severe toxicity in mice. |
Q45174780 | Experimental Infection of Specific-Pathogen-Free Mice with EnterohemorrhagicEscherichia coli0157: H7 |
Q40165986 | Experimental infection of infant rabbits with verotoxin-producing Escherichia coli. |
Q33353985 | Experimental verocytotoxemia in rabbits |
Q40268887 | Expression and characterization of the eaeA gene product of Escherichia coli serotype O157:H7. |
Q33493211 | Expression of A and B subunits of Shiga-like toxin II as fusions with glutathione S-transferase and their potential for use in seroepidemiology |
Q36505072 | Extended phage-typing scheme for Escherichia coli O157:H7 |
Q33489626 | Extrarenal involvement in diarrhoea-associated haemolytic-uraemic syndrome |
Q37142305 | Factors Associated with Shiga Toxin-Producing Escherichia coli Shedding by Dairy and Beef Cattle. |
Q33353982 | Failure to isolate verotoxin producing Escherichia coli from patients of haemolytic uremic syndrome |
Q37290075 | Fecal diagnostics in combination with serology: best test to establish STEC-HUS. |
Q36472867 | First recognized community outbreak of haemorrhagic colitis due to verotoxin-producing Escherichia coli O 157.H7 in the UK. |
Q41930818 | Focal segmental glomerulosclerosis associated with infantile spasms in five mentally retarded children: a morphological analysis on mesangiolysis |
Q24633220 | Foodborne illness acquired in the United States--unspecified agents |
Q40147730 | Frequent loss of Shiga-like toxin genes in clinical isolates of Escherichia coli upon subcultivation |
Q51783645 | Genetic Analysis of Virulence Potential of Escherichia coli O104 Serotypes Isolated From Cattle Feces Using Whole Genome Sequencing. |
Q92001002 | Genetic Diversity of Non-O157 Shiga Toxin-Producing Escherichia coli Recovered From Patients in Michigan and Connecticut |
Q38991043 | Genetic and Mechanistic Analyses of the Periplasmic Domain of the Enterohemorrhagic Escherichia coli QseC Histidine Sensor Kinase. |
Q42273128 | Genetic characteristics of Shiga toxin-producing E. coli O157, O26, O103, O111 and O145 isolates from humans, food, and cattle in Belgium. |
Q34107040 | Genetic diversity and virulence potential of shiga toxin-producing Escherichia coli O113:H21 strains isolated from clinical, environmental, and food sources |
Q36999232 | Genetic relationships among pathogenic Escherichia coli of serogroup O157 |
Q24624844 | Genome sequence analyses of two isolates from the recent Escherichia coli outbreak in Germany reveal the emergence of a new pathotype: Entero-Aggregative-Haemorrhagic Escherichia coli (EAHEC) |
Q36845551 | Genomic O island 122, locus for enterocyte effacement, and the evolution of virulent verocytotoxin-producing Escherichia coli. |
Q34114191 | Genomic subtraction to identify and characterize sequences of Shiga toxin-producing Escherichia coli O91:H21. |
Q41341761 | Genotypic characterization and prevalence of virulence factors among Canadian Escherichia coli O157:H7 strains |
Q33418419 | Globosides as key players in the pathophysiology of Shiga toxin-associated acute kidney failure and Fabry disease |
Q33387236 | Globotriaosyl ceramide receptor function - where membrane structure and pathology intersect |
Q38291919 | Globotriose-functionalized gold nanoparticles as multivalent probes for Shiga-like toxin |
Q54385143 | Globotriosyl ceramide is specifically recognized by the Escherichia coli verocytotoxin 2. |
Q37954161 | Glomerular fibrin deposition and removal |
Q33495323 | Glomerular ultrastructural lesions of idiopathic cutaneous and renal glomerular vasculopathy of greyhounds |
Q33330688 | Glycolipid receptors for verotoxin and Helicobacter pylori: role in pathology |
Q34394719 | Gnotobiotic piglet infection model for evaluating the safe use of antibiotics against Escherichia coli O157:H7 infection |
Q27026538 | HUS and TTP in Children |
Q33389799 | Haemolytic anaemia after childhood Escherichia coli O 157 .H7 infection: are females at increased risk? |
Q72797522 | Haemolytic anaemia in association with Escherichia coli O157 infection in two sisters |
Q33449632 | Haemolytic uraemic syndrome associated with Salmonella dysentery |
Q33447746 | Haemolytic uraemic syndrome associated with Yersinia enterocolitica infection |
Q33447741 | Haemolytic uraemic syndrome associated with faecal cytotoxin and verotoxin neutralizing antibodies |
Q33369703 | Haemolytic uraemic syndrome associated with interfamilial spread of E. coli O26:H11. |
Q33447267 | Haemolytic uraemic syndrome in adults |
Q33388780 | Haemolytic uraemic syndrome in the defined population of northeast of Scotland |
Q33397726 | Haemolytic uraemic syndromes in the British Isles 1985-8: association with verocytotoxin producing Escherichia coli. Part 1: Clinical and epidemiological aspects |
Q33397728 | Haemolytic uraemic syndromes in the British Isles, 1985-8: association with verocytotoxin producing Escherichia coli. Part 2: Microbiological aspects |
Q33403923 | Haemolytic-uraemic syndrome as a sequela of diarrhoeal disease |
Q33380619 | Haemolytic-uraemic syndrome associated with Aeromonas hydrophila enterocolitis |
Q33489318 | Haemolytic-uraemic syndrome in childhood: surveillance and case-control studies in Italy. Italian HUS Study Group |
Q33490805 | Haemolytic-uraemic syndrome in practice |
Q42744252 | Haemorrhagic colitis and Escherichia coli O157--a pathogen unmasked |
Q33370343 | Haemorrhagic colitis and haemolytic-uraemic syndrome: false positive reaction with a rotavirus latex agglutination test |
Q42841506 | Haemorrhagic colitis: detection of verotoxin producing Escherichia coli O157 in a clinical microbiology laboratory |
Q40208572 | HeLa cell adherence and cytotoxin production by enteropathogenic Escherichia coli isolated from infants with diarrhea in Thailand |
Q39890859 | Heat adaptation alters Escherichia coli O157:H7 membrane lipid composition and verotoxin production |
Q41033263 | Hemolytic disorders associated with cancer |
Q33429497 | Hemolytic uraemic syndrome following Salmonella typhimurium enteritis |
Q33453248 | Hemolytic uremic syndrome and diarrhea associated with Escherichia coli O157:H7 in a day care center |
Q33408648 | Hemolytic uremic syndrome complicating Mycoplasma pneumoniae infection |
Q33368494 | Hemolytic uremic syndrome due to Escherichia coli O157: H7 in a child with multiple infections |
Q33359891 | Hemolytic uremic syndrome induced by lipopolysaccharide and Shiga-like toxin |
Q24669689 | Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers |
Q37288569 | Hemolytic uremic syndrome: late renal injury and changing incidence-a single centre experience in Canada |
Q33435426 | Hemolytic-uremic syndrome (HUS) in children at the University Hospital Center in Dakar: about four cases |
Q33375240 | Hemolytic-uremic syndrome and myocardial dysfunction in a 9-month-old boy. |
Q33396501 | Hemolytic-uremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations |
Q53159950 | Hemolytic-uremic syndrome: a population-based study in Washington, DC and Baltimore, Maryland. |
Q68524105 | Hemorrhagic colitis and Escherichia coli O157:H7--identifying a messenger while pursuing the message |
Q34726358 | Hemorrhagic colitis due to Escherichia coli O157:H7. A rare disease? |
Q37812850 | Hepatobiliary Manifestations of Critically Ill and Postoperative Patients |
Q33337448 | Heterogeneity of Shiga toxin-producing Escherichia coli strains isolated from hemolytic-uremic syndrome patients, cattle, and food samples in central France |
Q33381234 | High incidence of serum antibodies to Escherichia coli O157 lipopolysaccharide in children with hemolytic-uremic syndrome |
Q49960179 | High-Quality Complete Genome Sequences of Three Bovine Shiga Toxin-Producing Escherichia coli O177:H- (fliCH25) Isolates Harboring Virulent stx2 and Multiple Plasmids |
Q33383017 | Host and pathogen determinants of verocytotoxin-producing Escherichia coli-associated hemolytic uremic syndrome |
Q33942303 | How does Escherichia coli O157:H7 testing in meat compare with what we are seeing clinically? |
Q33340641 | Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection |
Q39751395 | Identification and Characterization of a New Variant of Shiga Toxin 1 in Escherichia coli ONT:H19 of Bovine Origin |
Q37158316 | Identification of Escherichia coli serotype O157 strains by using a monoclonal antibody |
Q41749422 | Identification of O serotypes, genotypes, and virulotypes of Shiga toxin-producing Escherichia coli isolates, including non-O157 from beef cattle in Japan |
Q33494321 | Identification of a clone of Escherichia coli O103:H2 as a potential agent of hemolytic-uremic syndrome in France |
Q35534259 | Identification of a family of intimins common to Escherichia coli causing attaching-effacing lesions in rabbits, humans, and swine |
Q34643412 | Identification of a peptide-based neutralizer that potently inhibits both Shiga toxins 1 and 2 by targeting specific receptor-binding regions |
Q34933393 | Identification of a wide range of motifs inhibitory to shiga toxin by affinity-driven screening of customized divalent peptides synthesized on a membrane |
Q33221148 | Identification of four fimbria-encoding genomic islands that are highly specific for verocytotoxin-producing Escherichia coli serotype O157 strains |
Q39697637 | Identification, characterization, and distribution of a Shiga toxin 1 gene variant (stx(1c)) in Escherichia coli strains isolated from humans |
Q35892930 | Immune response to verotoxin 1 and 2 in children with Escherichia coli O157:H7 hemorrhagic colitis and classic hemolytic uremic syndrome |
Q33387170 | Immune thrombocytopenia in pregnancy |
Q38504443 | Immuno-based detection of Shiga toxin-producing pathogenic Escherichia coli in food - A review on current approaches and potential strategies for optimization |
Q40267335 | Immunocompromise in gnotobiotic pigs induced by verotoxin-producing Escherichia coli (O111:NM). |
Q43774740 | Immunohistochemical detection of verotoxin receptors in nervous system |
Q54377737 | Immunomodulating Activity of Lactobacillus paracasei subsp. paracasei NTU 101 in Enterohemorrhagic Escherichia coli O157H7-Infected Mice |
Q36521591 | Impact of free verotoxin testing on epidemiology of diarrhea caused by verotoxin-producing Escherichia coli. |
Q33492871 | Impaired antioxidant defense mechanisms in two children with hemolytic-uremic syndrome |
Q33359241 | Impaired detection of faecal verocytotoxin in the presence of Clostridium difficile cytotoxin in patients with haemolytic uraemic syndrome |
Q33366669 | Impaired neutrophils in children with the typical form of hemolytic uremic syndrome |
Q37211202 | Improved biochemical screening procedure for small clinical laboratories for vero (Shiga-like)-toxin-producing strains of Escherichia coli O157:H7. |
Q38323354 | In vitro assessment of a chemically synthesized Shiga toxin receptor analog attached to chromosorb P (Synsorb Pk) as a specific absorbing agent of Shiga toxin 1 and 2. |
Q45096420 | In vitro bactericidal activity of antimicrobial agents against enterohaemorrhagic Escherichia coli |
Q51375879 | Incidence and index of severity of hemolytic uremic syndrome in a 26 year period in Fukushima Prefecture, Japan. |
Q33489027 | Incomplete hemolytic-uremic syndrome in Argentinean children with bloody diarrhea |
Q54646115 | Increased globotriaosylceramide on plasma membranes of synchronized familial dysautonomia cells. Verotoxin binding studies. |
Q33837961 | Induction of verotoxin sensitivity in receptor-deficient cell lines using the receptor glycolipid globotriosylceramide |
Q33331859 | Infarction of the choledochus, liver, gallbladder, and pancreas: a unique complication of the hemolytic uremic syndrome |
Q33358878 | Infection by Shiga toxin-producing Escherichia coli: an overview |
Q36634680 | Infection by verocytotoxin-producing Escherichia coli |
Q37968453 | Infectious diarrhea. Managing a misery that is still worldwide |
Q40978125 | Infectious gastroenterocolitides in children: an update on emerging pathogens |
Q33551086 | Influence of Escherichia coli shiga toxin on the mammalian central nervous system |
Q52605063 | Influence of RNase E deficiency on the production of stx2-bearing phages and Shiga toxin in an RNase E-inducible strain of enterohaemorrhagic Escherichia coli (EHEC) O157:H7. |
Q46437878 | Influence of acetic, citric, and lactic acids on Escherichia coli O157:H7 membrane lipid composition, verotoxin secretion, and acid resistance in simulated gastric fluid |
Q38299550 | Influence of length and conformation of saccharide head groups on the mechanics of glycolipid membranes: Unraveled by off-specular neutron scattering |
Q38359579 | Influence of phospholipid chain length on verotoxin/globotriaosyl ceramide binding in model membranes: comparison of a supported bilayer film and liposomes |
Q33408179 | Inhibition of water absorption and selective damage to human colonic mucosa are induced by subtilase cytotoxin produced by Escherichia coli O113:H21 |
Q43810790 | Inhibitory activity of Bifidobacterium longum HY8001 against Vero cytotoxin of Escherichia coli O157:H7. |
Q40592342 | Interaction of Shiga toxin from Escherichia coli with human intestinal epithelial cell lines and explants: Stx2 induces epithelial damage in organ culture |
Q33357114 | Interleukin-8 and polymorphoneutrophil leucocyte activation in hemolytic uremic syndrome of childhood |
Q33768841 | Invasion of epithelial cells by locus of enterocyte effacement-negative enterohemorrhagic Escherichia coli |
Q33953014 | Investigating the global genomic diversity of Escherichia coli using a multi-genome DNA microarray platform with novel gene prediction strategies |
Q40162448 | Ionic requirements for entry of Shiga toxin from Shigella dysenteriae 1 into cells |
Q33337601 | Is immune cell activation the missing link in the pathogenesis of post-diarrhoeal HUS? |
Q37156797 | Isolation and characterization of monoclonal antibodies to Shiga-like toxin II of enterohemorrhagic Escherichia coli and use of the monoclonal antibodies in a colony enzyme-linked immunosorbent assay |
Q33502935 | Isolation and characterization of sorbitol-fermenting Shiga toxin (Verocytotoxin)-producing Escherichia coli O157:H- strains in the Czech Republic. |
Q44776680 | Isolation and characterization of the Shiga toxin gene (stx)-bearing Escherichia coli O157 and non-O157 from retail meats in Shandong Province, China, and characterization of the O157-derived stx2 phages |
Q73208404 | Isolation and characterization of verocytotoxin-producing Escherichia coli O157 from slaughter pigs and poultry |
Q33661058 | Isolation and characterization of verocytotoxin-producing Escherichia coli O157 strains from Dutch cattle and sheep. |
Q33396996 | Isolation in Italy of a verotoxin-producing strain of Escherichia coli O157:H7 from a child with hemolytic-uraemic syndrome. |
Q54774130 | Isolation of Escherichia coli O157:H7 from dairy cattle associated with two cases of haemolytic uraemic syndrome. |
Q33497617 | Isolation of enterohemorrhagic Escherichia coli O157 strains from patients with hemolytic-uremic syndrome by using immunomagnetic separation, DNA-based methods, and direct culture |
Q43054174 | Isolation of verocytotoxin-producing Escherichia coli from milk filters in south-western Ontario |
Q33373368 | Journey in reverse: TTP from bedside to blood bank to bench |
Q38342112 | Kinetic Analyses of Bindings of Shiga-like Toxin to Clustered and Dispersed Gb3 Glyco-Arrays on a Quartz-Crystal Microbalance |
Q40207879 | Laboratory investigation of outbreak of hemorrhagic colitis caused by Escherichia coli O157:H7. |
Q40200226 | Latex agglutination test for detection of Escherichia coli serotype O157. |
Q38305667 | Lipid modulation of glycolipid receptor function. Availability of Gal(alpha 1-4)Gal disaccharide for verotoxin binding in natural and synthetic glycolipids |
Q33497678 | Lipopolysaccharide-specific antibodies in plasma and stools of children with Shigella-associated leukemoid reaction and hemolytic-uremic syndrome |
Q39830255 | Localization of intravenously administered verocytotoxins (Shiga-like toxins) 1 and 2 in rabbits immunized with homologous and heterologous toxoids and toxin subunits |
Q33328565 | Localization of verotoxin receptors in nervous system. |
Q35324691 | Long term risk for hypertension, renal impairment, and cardiovascular disease after gastroenteritis from drinking water contaminated with Escherichia coli O157:H7: a prospective cohort study |
Q35754475 | Luminescence based enzyme-labeled phage (Phazyme) assays for rapid detection of Shiga toxin producing Escherichia coli serogroups. |
Q45855222 | M-COPA, a novel Golgi system disruptor, suppresses apoptosis induced by Shiga toxin |
Q35531436 | Magnetic resonance imaging and histopathological study of brain lesions in rabbits given intravenous verotoxin 2. |
Q33449519 | Management of hemolytic-uremic syndrome |
Q38604123 | Metapopulation dynamics of Escherichia coli O157 in cattle: an exploratory model |
Q33490231 | Microangiopathic hemolytic anemia and severe thrombocytopenia in Brucella infection |
Q54366958 | Microbead-based immunoassay for simultaneous detection of Shiga toxins and isolation of Escherichia coli O157 in foods. |
Q47127903 | Microvesicle Involvement in Shiga Toxin-Associated Infection |
Q43329511 | Mitigating the antimicrobial activities of selected organic acids and commercial sanitizers with various neutralizing agents |
Q71785854 | Modelling of the interaction of verotoxin-1 (VT1) with its glycolipid receptor, globotriaosylceramide (Gb3) |
Q43566476 | Modelling the epidemiology and transmission of Verocytotoxin-producing Escherichia coli serogroups O26 and O103 in two different calf cohorts |
Q40154302 | Modification of the glycolipid-binding specificity of vero cytotoxin by polymyxin B and other cyclic amphipathic peptides |
Q37009028 | Modulation of the enterohemorrhagic E. coli virulence program through the human gastrointestinal tract |
Q58870866 | Molecular Characterization of Shiga Toxin-ProducingEscherichia coli |
Q33378528 | Molecular analysis as an aid to assess the public health risk of non-O157 Shiga toxin-producing Escherichia coli strains |
Q30798461 | Molecular characterization of the locus encoding biosynthesis of the lipopolysaccharide O antigen of Escherichia coli serotype O113 |
Q41873961 | Molecular damage and induction of proinflammatory cytokines in human endothelial cells exposed to Shiga toxin 1, Shiga toxin 2, and alpha-sarcin |
Q34041771 | Molecular profiling and phenotype analysis of Escherichia coli O26:H11 and O26:NM: secular and geographic consistency of enterohemorrhagic and enteropathogenic isolates |
Q33502724 | Monocyte chemoattractant protein-1 and interleukin-8 levels in urine and serum of patents with hemolytic uremic syndrome |
Q40815072 | Morphological and intracellular alterations induced by cytotoxin VT2y produced by Escherichia coli isolated from chickens with swollen head syndrome |
Q36986374 | Mouse model for colonization and disease caused by enterohemorrhagic Escherichia coli O157:H7 |
Q34497115 | Mouse models of Escherichia coli O157:H7 infection and shiga toxin injection |
Q34005780 | Mouse toxicity and cytokine release by verotoxin 1 B subunit mutants |
Q35551789 | Murine antibody responses to the verotoxin 1 B subunit: demonstration of major histocompatibility complex dependence and an immunodominant epitope involving phenylalanine 30 |
Q33490306 | Myeloproliferative and metabolic causes |
Q33489463 | Myocarditis and haemolytic uraemic syndrome. |
Q33338235 | Nationwide study of haemolytic uraemic syndrome: clinical, microbiological, and epidemiological features. |
Q30300135 | Natural killer T (NKT) cells accelerate Shiga toxin type 2 (Stx2) pathology in mice |
Q42973858 | Nephrology, dialysis and transplantation |
Q40203480 | Neutralization receptor-based immunoassay for detection of neutralizing antibodies to Escherichia coli verocytotoxin 1. |
Q38300698 | Neutralizing activity of polyvalent Gb3, Gb2 and galacto-trehalose models against Shiga toxins |
Q39432827 | Neutralizing antibodies to Escherichia coli Vero cytotoxin 1 and antibodies to O157 lipopolysaccharide in healthy farm family members and urban residents. |
Q33965188 | Neutralizing antibodies to Shiga toxin type 2 (Stx2) reduce colonization of mice by Stx2-expressing Escherichia coli O157:H7. |
Q69375699 | Neutrophil elastases and haemolytic uraemic syndrome |
Q30434555 | New developments in enteric bacterial toxins |
Q36539801 | New immuno-PCR assay for detection of low concentrations of shiga toxin 2 and its variants |
Q33409878 | New insights into Shiga toxin-mediated endothelial dysfunction in hemolytic uremic syndrome |
Q33397724 | New insights into the haemolytic uraemic syndromes |
Q43967019 | Nitric oxide-mediated apoptosis in rat macrophages subjected to Shiga toxin 2 from Escherichia coli |
Q43874437 | Nitrobenzylthioinosine (NBT), a nucleoside transport inhibitor, protects against Shiga toxin cytotoxicity in human microvascular endothelial cells |
Q42142131 | Novel repressor of Escherichia coli O157:H7 motility encoded in the putative fimbrial cluster OI-1. |
Q36265701 | Nucleotide sequence and promoter mapping of the Escherichia coli Shiga-like toxin operon of bacteriophage H-19B. |
Q34633814 | Nucleotide sequence of the Shiga-like toxin genes of Escherichia coli |
Q43607603 | Occurrence of Escherichia coli O157 in Finnish cattle |
Q50124787 | Occurrence of Vibrio and other pathogenic bacteria in Mytilus galloprovincialis (mussels) harvested from Adriatic Sea, Italy |
Q42598711 | Occurrence of subtilase cytotoxin and relation with other virulence factors in verocytotoxigenic Escherichia coli isolated from food and cattle in Argentina |
Q33684744 | Occurrence of verocytotoxin-producing Escherichia coli O157 on Dutch dairy farms |
Q34128036 | One of two copies of the gene for the activatable shiga toxin type 2d in Escherichia coli O91:H21 strain B2F1 is associated with an inducible bacteriophage |
Q37643869 | Oral intoxication of mice with Shiga toxin type 2a (Stx2a) and protection by anti-Stx2a monoclonal antibody 11E10. |
Q38674148 | Ouabain Protects Human Renal Cells against the Cytotoxic Effects of Shiga Toxin Type 2 and Subtilase Cytotoxin |
Q33499151 | Outbreak of Escherichia coli O157:H7 infection in a large family |
Q33419782 | Overview and Historical Perspectives |
Q57676134 | PATHOGENESIS OF HAEMOLYTIC URAEMIC SYNDROME |
Q43518801 | Passive protection of purified yolk immunoglobulin administered against Shiga toxin 1 in mouse models |
Q24550740 | Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections |
Q33712512 | Pathogenesis of Escherichia coli O157:H7 strain 86-24 following oral infection of BALB/c mice with an intact commensal flora |
Q33338331 | Pathogenesis of Shiga toxin-associated hemolytic uremic syndrome. |
Q33445806 | Pathogenesis of the hemolytic uremic syndromes: current concepts |
Q41513764 | Pathogenic Escherichia coli: a new etiology for acute ileitis in children |
Q27003178 | Pathogenicity, host responses and implications for management of enterohemorrhagic Escherichia coli O157:H7 infection |
Q33359875 | Phenotypic and genotypic analyses of enterohemorrhagic Escherichia coli O145 strains from patients in Germany |
Q40150192 | Physicochemical and biological properties of purified Escherichia coli Shiga-like toxin II variant. |
Q39825714 | Polysaccharide side chains are not required for attaching and effacing adhesion of Escherichia coli O157:H7. |
Q33388706 | Post-transplantation outcome of patients with hemolytic-uremic syndrome: update |
Q28333178 | Postpartum haemolytic uraemic syndrome precipitated by antibiotics. Case report |
Q67913265 | Preparation of VT1 and VT2 hybrid toxins from their purified dissociated subunits. Evidence for B subunit modulation of a subunit function |
Q34545082 | Preparation, characterization, and immunological properties in mice of Escherichia coli O157 O-specific polysaccharide-protein conjugate vaccines |
Q33331011 | Pretreatment of mice with lipopolysaccharide (LPS) or IL-1beta exerts dose-dependent opposite effects on Shiga toxin-2 lethality |
Q33965946 | Prevalence and characterization of Shiga toxin-producing Escherichia coli isolated from cattle, food, and children during a one-year prospective study in France |
Q34316000 | Prevalence and virulence factors of Escherichia coli serogroups O26, O103, O111, and O145 shed by cattle in Scotland |
Q41883438 | Prevalence of Escherichia Coli O157:H7 and Enterobacteriaceae on Hands of Workers in Halal Cattle Abattoirs in Peninsular Malaysia |
Q36295186 | Prevalence of Shiga toxin-producing Escherichia coli in beef cattle |
Q43197024 | Prevalence of non-O157:H7 shiga toxin-producing Escherichia coli in diarrheal stool samples from Nebraska |
Q35598866 | Prevalence of shiga toxin-producing Escherichia coli as detected by enzyme-linked immunoassays and real-time PCR during the summer months in northern Alberta, Canada |
Q36503463 | Prevalence of the eaeA gene in verotoxigenic Escherichia coli strains from dairy cattle in Southwest Ontario |
Q36505009 | Prevalence of verocytotoxigenic Escherichia coli in ground beef, pork, and chicken in southwestern Ontario |
Q33989285 | Prevalence, antibiotic susceptibility, and diversity of Escherichia coli O157:H7 isolates from a longitudinal study of beef cattle feedlots |
Q43242940 | Prevention of Escherichia coli O157:H7 infection in gnotobiotic mice associated with Bifidobacterium strains |
Q33370606 | Procalcitonin in children with Escherichia coli O157:H7 associated hemolytic uremic syndrome |
Q33387199 | Production and characterization of a monoclonal antibody specific for enterohemorrhagic Escherichia coli of serotypes O157:H7 and O26:H11. |
Q36543571 | Production and characterization of monoclonal antibodies specific for the lipopolysaccharide of Escherichia coli O157 |
Q33344261 | Production and characterization of protective human antibodies against Shiga toxin 1 |
Q24647895 | Production of Shiga-like toxin among Escherichia coli strains and other bacteria isolated from diarrhea in São Paulo, Brazil |
Q71598028 | Production of Shiga-like toxins by Escherichia coli O157:H7 can be influenced by the neuroendocrine hormone norepinephrine |
Q54442866 | Production of shiga toxin by a luxS mutant of Escherichia coli O157:H7 in vivo and in vitro. |
Q37218835 | Promoter sequence of Shiga toxin 2 (Stx2) is recognized in vivo, leading to production of biologically active Stx2. |
Q33428960 | Properties of Vero cytotoxin-producing Escherichia coli of human and animal origin belonging to serotypes other than O157:H7 |
Q36472567 | Properties of strains of Escherichia coli belonging to serogroup O157 with special reference to production of Vero cytotoxins VT1 and VT2 |
Q35946861 | Proteasome inhibitors prevent cell death and prolong survival of mice challenged by Shiga toxin |
Q35012362 | Protection against Shiga toxin 1 challenge by immunization of mice with purified mutant Shiga toxin 1. |
Q39824053 | Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR. |
Q64118824 | Proteomic Analysis of Novel Components of Jellyfish Venom: Deciphering the Mode of Action |
Q33414067 | Purification and characterization of a phage-encoded cytotoxin from an Escherichia coli O111 strain associated with hemolytic-uremic syndrome |
Q38360747 | Purification of Shiga-like toxin 1 by pigeon egg white glycoproteins immobilized on Sepharose gels |
Q40200609 | Purification of an Escherichia coli serogroup O157:H7 verotoxin and its detection in North American hemorrhagic colitis isolates. |
Q34545284 | Purified Shiga-like toxins induce expression of proinflammatory cytokines from murine peritoneal macrophages |
Q50093767 | Putative virulence factors and clonal relationship of O174 Shiga toxin-producing Escherichia coli isolated from human, food and animal sources |
Q36226910 | Quantitative Detection of Shiga Toxins Directly from Stool Specimens of Patients Associated with an Outbreak of Enterohemorrhagic Escherichia coli in Japan--Quantitative Shiga toxin detection from stool during EHEC outbreak |
Q37001708 | Quantitative analysis and partial characterization of cytotoxin production by Salmonella strains |
Q73441776 | RNA aptamers that bind to and inhibit the ribosome-inactivating protein, pepocin |
Q30310781 | Rapid Apoptosis Induced by Shiga Toxin in HeLa Cells |
Q41895684 | Rapid and sensitive method for detection of Shiga-like toxin-producing Escherichia coli in ground beef using the polymerase chain reaction |
Q33415662 | Rapid diagnosis of Streptococcus pneumoniae-induced haemolytic-uraemic syndrome |
Q37174239 | Rapid method to detect shiga toxin and shiga-like toxin I based on binding to globotriosyl ceramide (Gb3), their natural receptor |
Q36455874 | Reactive oxygen molecules, oxidant injury and renal disease |
Q33397981 | Recent advances in understanding the pathogenesis of the hemolytic uremic syndromes |
Q33395662 | Recent progress of Shiga toxin neutralizer for treatment of infections by Shiga toxin-producing Escherichia coli |
Q53224717 | Recombinant Shiga toxin B subunit elicits protection against Shiga toxin via mixed Th type immune response in mice. |
Q33345537 | Recurrent hemolytic uremic syndrome |
Q36420818 | Recycling of Shiga toxin 2 genes in sorbitol-fermenting enterohemorrhagic Escherichia coli O157:NM |
Q35673972 | Reduced Toxicity of Shiga Toxin (Stx) Type 2c in Mice Compared to Stx2d Is Associated with Instability of Stx2c Holotoxin. |
Q73407888 | Reduction of fecal shedding of enterohemorrhagic Escherichia coli O157:H7 in lambs by feeding microbial feed supplement |
Q40564019 | Regulation of proinflammatory cytokine expression by Shiga toxin 1 and/or lipopolysaccharides in the human monocytic cell line THP-1 |
Q33383019 | Relationship between Escherichia coli O157:H7 and diabetes mellitus |
Q33335748 | Relationship between susceptibility to hemolytic-uremic syndrome and levels of globotriaosylceramide in human sera |
Q45218594 | Results of a 6-month survey of stool cultures for Escherichia coli O157:H7. |
Q36548021 | Reversed passive latex agglutination assay for detection of toxigenic Corynebacterium diphtheriae |
Q48033924 | Risk factors for infection with verocytotoxigenic Escherichia coli in cattle on Ontario dairy farms |
Q33357383 | Risk factors for poor renal prognosis in children with hemolytic uremic syndrome |
Q33396504 | Risk factors for the progression of Escherichia coli O157:H7 enteritis to hemolytic-uremic syndrome |
Q33502574 | Risk of hemolytic uremic syndrome after sporadic Escherichia coli O157:H7 infection: results of a Canadian collaborative study. Investigators of the Canadian Pediatric Kidney Disease Research Center |
Q40160973 | Role of a 60-megadalton plasmid and Shiga-like toxins in the pathogenesis of infection caused by enterohemorrhagic Escherichia coli O157:H7 in gnotobiotic piglets. |
Q34363235 | Role of iron in regulation of virulence genes |
Q33748229 | Role of tumor necrosis factor alpha in gnotobiotic mice infected with an Escherichia coli O157:H7 strain |
Q33404500 | Role of vascular endothelial growth factor and angiopoietin 1 in renal injury in hemolytic uremic syndrome |
Q33403359 | STEC-HUS, atypical HUS and TTP are all diseases of complement activation |
Q40204465 | Sensitive method for detecting low numbers of verotoxin-producing Escherichia coli in mixed cultures by use of colony sweeps and polymyxin extraction of verotoxin |
Q40200136 | Sensitive receptor-specified enzyme-linked immunosorbent assay for Escherichia coli verocytotoxin |
Q39109154 | Sensitivity of an immunomagnetic-separation-based test for detecting Escherichia coli O26 in bovine feces. |
Q33491633 | Serodiagnosis by passive hemagglutination test and verotoxin enzyme-linked immunosorbent assay of toxin-producing Escherichia coli infections in patients with hemolytic-uremic syndrome. |
Q33412829 | Serodiagnosis using microagglutination assay during the food-poisoning outbreak in Japan caused by consumption of raw beef contaminated with enterohemorrhagic Escherichia coli O111 and O157 |
Q43558451 | Serological differences between verocytotoxin 2 and shiga-like toxin II. |
Q33395389 | Serological response of Shiga toxin-producing Escherichia coli type III secreted proteins in sera from vaccinated rabbits, naturally infected cattle, and humans |
Q36973479 | Serological responses to the B subunit of Shiga-like toxin 1 and its peptide fragments indicate that the B subunit is a vaccine candidate to counter action of the toxin |
Q37235962 | Serotype O157:H7 Escherichia coli from bovine and meat sources |
Q33426514 | Serum antibodies to Escherichia coli serotype O157:H7 in patients with hemolytic uremic syndrome |
Q35493730 | Serum antibody responses of cattle following experimental infection with Escherichia coli O157:H7 |
Q35616704 | Severe acute diarrhea |
Q33364719 | Severe thrombotic microangiopathy associated with brucellosis: successful treatment with plasmapheresis |
Q36713756 | Shiga Toxin-Producing Escherichia coli in Plateau Pika (Ochotona curzoniae) on the Qinghai-Tibetan Plateau, China |
Q40143836 | Shiga Toxin-Producing Serogroup O91 Escherichia coli Strains Isolated from Food and Environmental Samples |
Q37063416 | Shiga and Shiga-like toxins |
Q36669065 | Shiga toxin 'goes retro' in human primary kidney cells |
Q42920438 | Shiga toxin 1 and ricin A chain bind to human polymorphonuclear leucocytes through a common receptor |
Q54454112 | Shiga toxin activatable by intestinal mucus in Escherichia coli isolated from humans: predictor for a severe clinical outcome. |
Q35869756 | Shiga toxin gene loss and transfer in vitro and in vivo during enterohemorrhagic Escherichia coli O26 infection in humans |
Q26850758 | Shiga toxin interaction with human intestinal epithelium |
Q33413792 | Shiga toxin production and translocation during microaerobic human colonic infection with Shiga toxin-producing E. coli O157:H7 and O104:H4 |
Q54456633 | Shiga toxin-1 affects nitric oxide production by human glomerular endothelial and mesangial cells. |
Q33363208 | Shiga toxin-associated hemolytic uremic syndrome: combined cytotoxic effects of shiga toxin and lipopolysaccharide (endotoxin) on human vascular endothelial cells in vitro. |
Q33489940 | Shiga toxin-associated hemolytic uremic syndrome: effect of sodium butyrate on sensitivity of human umbilical vein endothelial cells to Shiga toxin. |
Q33389321 | Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction |
Q33384145 | Shiga toxin-associated hemolytic-uremic syndrome: combined cytotoxic effects of Shiga toxin, interleukin-1 beta, and tumor necrosis factor alpha on human vascular endothelial cells in vitro |
Q33599604 | Shiga toxin-induced tumor necrosis factor alpha expression: requirement for toxin enzymatic activity and monocyte protein kinase C and protein tyrosine kinases |
Q30439707 | Shiga toxin-mediated disease in MyD88-deficient mice infected with Escherichia coli O157:H7. |
Q45282761 | Shiga toxin-producing Escherichia coli in Central Greece: prevalence and virulence genes of O157:H7 and non-O157 in animal feces, vegetables, and humans |
Q34000479 | Shiga toxin-producing Escherichia coli in swine: the public health perspective |
Q33342197 | Shiga toxin-producing Escherichia coli infection and antibodies against Stx2 and Stx1 in household contacts of children with enteropathic hemolytic-uremic syndrome |
Q35844728 | Shiga toxin-producing Escherichia coli serotype O78:H(-) in family, Finland, 2009. |
Q33383432 | Shiga toxin-producing Escherichia coli strains negative for locus of enterocyte effacement |
Q33404640 | Shiga toxins and the pathophysiology of hemolytic uremic syndrome in humans and animals |
Q33370181 | Shiga toxins present in the gut and in the polymorphonuclear leukocytes circulating in the blood of children with hemolytic-uremic syndrome |
Q33330360 | Shiga toxins stimulate secretion of interleukin-8 from intestinal epithelial cells |
Q46937282 | Shiga-like toxin production and connective tissue protein binding of Escherichia coli isolated from a patient with ulcerative colitis |
Q27621547 | Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands |
Q42125743 | Shiga-like-toxin-producing Escherichia coli in retail meats and cattle in Thailand |
Q39822837 | Signal transduction responses following adhesion of verocytotoxin-producing Escherichia coli |
Q56892711 | Single chain variable fragment antibodies against Shiga toxins isolated from a human antibody phage display library |
Q40197674 | Single primer pair for amplifying segments of distinct Shiga-like-toxin genes by polymerase chain reaction |
Q41925990 | Sorbitol-Fermenting Enterohemorrhagic Escherichia coli O157:H- Isolates from Czech Patients with Novel Plasmid Composition Not Previously Seen in German Isolates |
Q40205809 | Sorbitol-MacConkey medium for detection of Escherichia coli O157:H7 associated with hemorrhagic colitis |
Q28743696 | Specific egg yolk immunoglobulin as a new preventive approach for Shiga-toxin-mediated diseases |
Q42705126 | Specific inhibitory action of anisodamine against a staphylococcal superantigenic toxin, toxic shock syndrome toxin 1 (TSST-1), leading to down-regulation of cytokine production and blocking of TSST-1 toxicity in mice |
Q33490963 | Spectrum of extrarenal involvement in postdiarrheal hemolytic-uremic syndrome |
Q33379319 | Sporadic bloody diarrhoea-associated thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome: an adult and paediatric comparison |
Q33334110 | Staphylococcus aureus bacteremia as a cause of early relapse of thrombotic thrombocytopenic purpura |
Q38315562 | Structural analysis of the interaction between Shiga toxin B subunits and linear polymers bearing clustered globotriose residues. |
Q37428553 | Study on induction of apoptosis on HeLa and Vero cells by recombinant shiga toxin and its subunits. |
Q35931886 | Sub-Lethal Dose of Shiga Toxin 2 from Enterohemorrhagic Escherichia coli Affects Balance and Cerebellar Cytoarchitecture |
Q40163784 | Surface properties of the Vero cytotoxin-producing Escherichia coli O157:H7. |
Q46167654 | Survival of Escherichia coli O157:H7 in traditional African yoghurt fermentation |
Q54682708 | Susceptibility to verotoxin as a function of the cell cycle |
Q34002606 | Syntheses and immunologic properties of Escherichia coli O157 O-specific polysaccharide and Shiga toxin 1 B subunit conjugates in mice. |
Q44581071 | Synthesis of galactose-containing oligosaccharides through superbeads and superbug approaches: substrate recognition along different biosynthetic pathways |
Q44588733 | Target-selective photo-degradation of verotoxin-1 and reduction of its cytotoxicity to Vero cells using porphyrin-globotriose hybrids. |
Q28592771 | Targeted disruption of Gb3/CD77 synthase gene resulted in the complete deletion of globo-series glycosphingolipids and loss of sensitivity to verotoxins |
Q36929589 | Temporal shedding patterns and virulence factors of Escherichia coli serogroups O26, O103, O111, O145, and O157 in a cohort of beef calves and their dams |
Q37182771 | The Accessory Genome of Shiga Toxin-Producing Escherichia coli Defines a Persistent Colonization Type in Cattle |
Q33428611 | The Antibiotic Polymyxin B Impairs the Interactions between Shiga Toxins and Human Neutrophils. |
Q92537986 | The Association of Cell Division Regulated by DicC With the Formation of Viable but Non-culturable Escherichia coli O157:H7 |
Q38160938 | The Canadian contribution to the science of verotoxigenic Escherichia coli and associated illnesses: the early years |
Q27680604 | The Crystal Structure of Shiga Toxin Type 2 with Bound Disaccharide Guides the Design of a Heterobifunctional Toxin Inhibitor |
Q33378414 | The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome Registry: the Swiss connection |
Q40552744 | The P blood group system: biochemical, serological, and clinical aspects |
Q54502689 | The Shiga toxin 2 B subunit inhibits net fluid absorption in human colon and elicits fluid accumulation in rat colon loops. |
Q24563989 | The bacterial colicin active against tumor cells in vitro and in vivo is verotoxin 1 |
Q90042170 | The bacterial instrument as a promising therapy for colon cancer |
Q33504952 | The detection of Shiga toxins in the kidney of a patient with hemolytic uremic syndrome |
Q33420531 | The efficacy of recombinant human soluble thrombomodulin for the treatment of shiga toxin-associated hemolytic uremic syndrome model mice |
Q41215965 | The emergency department approach to diarrhea |
Q33398109 | The expression of blood group P1 in post-enteropathic haemolytic uraemic syndrome |
Q57704288 | The hemolytic uremic syndrome |
Q71041946 | The hemolytic uremic syndrome |
Q33503414 | The hemolytic uremic syndrome as a complication of adriamycin nephropathy |
Q33445781 | The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections. |
Q40949783 | The identification of three biologically relevant globotriaosyl ceramide receptor binding sites on the Verotoxin 1 B subunit |
Q38022246 | The interactions of human neutrophils with shiga toxins and related plant toxins: danger or safety? |
Q41812822 | The isolation rate of Escherichia coli 0157:H7 in Toronto and surrounding communities |
Q42856082 | The mode of action of Shiga toxin on peptide elongation of eukaryotic protein synthesis |
Q33376042 | The pathogenic mechanisms of Shiga toxin and the Shiga-like toxins |
Q69395934 | The pathophysiology of Hirschsprung's-associated enterocolitis: importance of histologic correlates |
Q34081045 | The prevalence of verocytotoxin-producing Escherichia coli and antimicrobial resistance patterns of nonverocytotoxin-producing Escherichia coli and Salmonella in Ontario broiler chickens |
Q24623245 | The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections |
Q33494653 | The role of Escherichia coli O 157 infections in the classical (enteropathic) haemolytic uraemic syndrome: results of a Central European, multicentre study |
Q54648744 | The role of tyrosine-114 in the enzymatic activity of the Shiga-like toxin I A-chain. |
Q35773392 | The specific activities of Shiga-like toxin type II (SLT-II) and SLT-II-related toxins of enterohemorrhagic Escherichia coli differ when measured by Vero cell cytotoxicity but not by mouse lethality |
Q33445858 | The use of sorbitol-MacConkey agar in conjunction with a specific antiserum for the detection of Vero cytotoxin-producing strains of Escherichia coli O 157. |
Q35018603 | Three years experience of adults admitted to hospital in north-east Scotland with E. coli O157. |
Q33374370 | Thrombotic microangiopathies: an update |
Q33389435 | Thrombotic microangiopathies: multimers, metalloprotease, and beyond |
Q35098992 | Thrombotic microangiopathy in haematopoietic cell transplantation: an update |
Q33393240 | Thrombotic microangiopathy in systemic lupus erythematosus: a cohort study in North Taiwan |
Q33399520 | Thrombotic microangiopathy: current knowledge and outcomes with plasma exchange |
Q33339090 | Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS): the new thinking |
Q33369006 | Thrombotic thrombocytopenic purpura mimicking acute small bowel Crohn's disease |
Q33354806 | Thrombotic thrombocytopenic purpura: outcome in 24 patients with renal impairment treated with plasma exchange. Canadian Apheresis Study Group |
Q43675858 | Tolerance to lipopolysaccharide (LPS) regulates the endotoxin effects on Shiga toxin-2 lethality |
Q39829974 | Toxicity and immunogenicity of a verotoxin 1 mutant with reduced globotriaosylceramide receptor binding in rabbits. |
Q33719947 | Transcriptional analysis of genes encoding Shiga toxin 2 and its variants in Escherichia coli |
Q36375176 | Transfer region of pO113 from enterohemorrhagic Escherichia coli: similarity with R64 and identification of a novel plasmid-encoded autotransporter, EpeA |
Q35512892 | Translocation of Shiga toxin across polarized intestinal cells in tissue culture |
Q33380757 | Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS). |
Q33499711 | Treatment of plasma refractory thrombotic thrombocytopenic purpura with protein A immunoabsorption |
Q69870583 | Two distinct toxins active on Vero cells from Escherichia coli O157 |
Q24646436 | Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities |
Q34002950 | Typing of intimin genes in human and animal enterohemorrhagic and enteropathogenic Escherichia coli: characterization of a new intimin variant |
Q37322141 | Update on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations |
Q37224766 | Use of a Chinese hamster ovary cell cytotoxicity assay for the rapid diagnosis of pertussis |
Q58590838 | Use of camel single-domain antibodies for the diagnosis and treatment of zoonotic diseases |
Q87408599 | Use of clustered regularly interspaced short palindromic repeat sequence polymorphisms for specific detection of enterohemorrhagic Escherichia coli strains of serotypes O26:H11, O45:H2, O103:H2, O111:H8, O121:H19, O145:H28, and O157:H7 by real-time |
Q39821292 | Use of heme and hemoglobin by Escherichia coli O157 and other Shiga-like-toxin-producing E. coli serogroups |
Q36543530 | Use of the flagellar H7 gene as a target in multiplex PCR assays and improved specificity in identification of enterohemorrhagic Escherichia coli strains |
Q28610949 | Utility of Whole-Genome Sequencing of Escherichia coli O157 for Outbreak Detection and Epidemiological Surveillance |
Q35461166 | Vaccination with genetically modified Shiga-like toxin IIe prevents edema disease in swine |
Q38526159 | Vascular ultrastructure and DNA fragmentation in swine infected with Shiga toxin-producing Escherichia coli |
Q33398393 | Vero cytotoxin-producing strains of Escherichia coli in children with haemolytic uraemic syndrome and diarrhoea in Czechoslovakia |
Q37467549 | Verocytotoxin-producing Escherichia coli (VTEC). |
Q59256479 | Verocytotoxin-producing Escherichia coli in foodstuffs of animal origin |
Q33497037 | Verocytotoxin-producing Escherichia coli infection in hemolytic uremic syndrome in part of western Europe. |
Q33721614 | Verocytotoxins (Shiga-like toxins) produced by Escherichia coli: a minireview of their classification, clinical presentations and management of a heterogeneous family of cytotoxins |
Q33391604 | Verotoxigenic (enterohaemorrhagic) Escherichia coli in infants and toddlers in Czechoslovakia |
Q36170601 | Verotoxigenic Escherichia coli (VTEC): a major public health threat in Canada |
Q91975349 | Verotoxin Receptor-Based Pathology and Therapies |
Q33383004 | Verotoxin biology: molecular events in vascular endothelial injury |
Q36752008 | Verotoxin induces hemorrhagic lesions in rat small intestine. Temporal alteration of vasoactive substances |
Q39488477 | Verotoxin-producing Escherichia coli (VTEC) infection in randomly selected population of Ilam Province (Iran). |
Q33427915 | Verotoxin-producing Escherichia coli infections in Sheffield: cattle as a possible source |
Q42164073 | Verotoxins in bovine and meat verotoxin-producing Escherichia coli isolates: type, number of variants, and relationship to cytotoxicity. |
Q40979852 | Verotoxins inhibit the growth of and induce apoptosis in human astrocytoma cells |
Q42120585 | Virulence Characterization of Shiga-Toxigenic Escherichia coli Isolates from Wholesale Produce |
Q93006047 | Virulence Profiling and Molecular Typing of Shiga Toxin-Producing E. coli (STEC) from Human Sources in Brazil |
Q33608157 | Virulence of enterohemorrhagic Escherichia coli O91:H21 clinical isolates in an orally infected mouse model |
Q46797072 | Yersinia and haemolytic uraemic syndrome |
Q74167972 | [Verotoxin-producing Escherichia coli infections: study of its prevalence in children in the Auvergne region] |
Q33369655 | stx2vha is the dominant genotype of Shiga toxin-producing Escherichia coli O157:H7 isolated from patients and domestic animals in three regions of China |
Q33394292 | von Willebrand factor in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome |
Search more.